Literature DB >> 28008657

Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Elisabet Størset1,2, Kristine Hole3, Karsten Midtvedt1, Stein Bergan4,5, Espen Molden3,4, Anders Åsberg1,4.   

Abstract

Entities:  

Keywords:  4β-hydroxycholesterol; CYP3A; bodyweight; kidney transplantation; tacrolimus

Mesh：

Substances：

Year:  2016        PMID： 28008657      PMCID： PMC5427239          DOI： 10.1111/bcp.13188

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

Review 1.  Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.

Authors:  Thomas Vanhove; Pieter Annaert; Dirk R J Kuypers
Journal:  Drug Metab Rev       Date:  2016-02-25       Impact factor: 4.518

2.  Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2016-12-22       Impact factor: 4.335

3.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

Review 4.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

5.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

6.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971
  6 in total
  5 in total

1.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

2.  Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-04-03       Impact factor: 4.335

3.  Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Authors:  Thomas Vanhove; Pieter Annaert; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2017-02-20       Impact factor: 4.335

4.  4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.

Authors:  Caroline Gjestad; Tore Haslemo; Ole A Andreassen; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2017-07-21       Impact factor: 4.335

5.  Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2016-12-22       Impact factor: 4.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.